Company: PACB
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001299130-25-000102
Chunk: 212

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 212
---
 of the contingent consideration liability for the three months ended March 31, 2025 were as follows:(In thousands)Level 3Beginning balance as of December 31, 2024$18,700 Change in estimated fair value(18,700)Ending balance as of March 31, 2025$— Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statement of operations and comprehensive loss.

Q1 Fiscal 2025 Form 10-Q11

Cash, Cash Equivalents, Restricted Cash, and InvestmentsThe following tables summarize our cash, cash equivalents, restricted cash, and investments:As of March 31, 2025(In thousands)AmortizedCost GrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents$58,507 $1 $(1)$58,507 Investments:Corporate debt securities 38,635 169 (14)38,790 U.S. government & agency securities245,587 283 (57)245,813 Total investments 284,222 452 (71)284,603 Total cash, cash equivalents and investments $342,729 $453 $(72)$343,110 Short-term restricted cash$690 $— $— $690 Long-term restricted cash$1,532 $— $— $1,532 As of December 31, 2024(In thousands)AmortizedCostGrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents$55,370 $— $— $55,370 Investments:Corporate debt securities46,746 184 (25)46,905 U.S. government & agency securities287,393 418 (155)287,656 Total investments334,139 602 (180)334,561 Total cash, cash equivalents and investments$389,509 $602 $(180)$389,931 Short-term restricted cash$690 $— $— $690 Long-term restricted cash$1,532 $— $— $1,532 The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March 31, 2025:(In thousands)Fair ValueDue in one year or less $227,680 Due